Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (November 2024)
12 slides from Island Pharmaceuticals's investor presentation, Nov 27, 2024
Slide 1: Combatting Urgent Viral Disease Threats
For personal use only COMBATTING URGENT VIRAL DISEASE THREATS DR DAVID FOSTER, MANAGING DIRECTOR 27 November 2024 (ASX: ILA) ISLAND PHARMACEUTICALS 1 November 2024
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financia
Slide 3: Island Pharmaceuticals is an antiviral therapeutics company targeting infectious diseases
For personal use only Island Pharmaceuticals (ASX:ILA) is an antiviral therapeutics company targeting infectious diseases ISLAND PHARMACEUTICALS 3 November 2024
Slide 4: Rapid Paths to Market
For personal use only ASSETS: - Known small molecules with clinical history - Mid/late stage clinical or other abbreviated routes - Open USFDA INDs - Validated US Govt/military funding support - Priority Review Voucher eligible RAPID PATHS TO MARKET ISLAND PHARMACEUTICALS 4 November 2024
Slide 5: Island at a Glance
ISLAND (ASX: ILA) AT A GLANCE For personal use only Dengue infects up Major market to 400m per year* potential Positive results in Phase 2a/b PROTECT clinical aggressive models trial in dengue underway Priority Review Pipeline expansion Voucher potential in progress ISLAND PHARMACEUTICALS 5 November
Slide 6: ISLA-101 Broad Activity Evident
ISLA-101 BROAD ACTIVITY EVIDENT For personal use only Demonstrated activity against flaviviruses (a subgroup of arboviruses) in multiple models of infection • In in-vitro models ISLA-101 has demonstrated broad anti-viral activity Dengue • In in-vitro models using fresh human cells, ISLA-101 has 1-4
Slide 7: Phase 2a/b Dengue (PROTECT) Trial Study
PHASE 2a/b DENGUE (PROTECT) TRIAL STUDY For personal use only “PROTECT" study- A Phase 2a/b, Randomized, Double Phase 2a/b trial protocol: 2 cohorts blind, Placebo-controlled Dengue Challenge Study – a 1. Prophylactic Cohort- 2A: 4 subjects randomized 3:1 PROphylactic and TrEatment Challenge Trial 2
Slide 8: Phase 2a/b Clinical Trial Design
PHASE 2a/b CLINICAL TRIAL DESIGN For personal use only Phase 2a/b trial protocol: 2 cohorts Key near-term milestones: 1. Prophylactic Cohort- 2a (left): 4 subjects randomized 3:1 • Ethics approval received in August 2024, patient 2. Therapeutic Cohort: 2b (right): 10 subjects randomized 8:2 screenin
Slide 9: Phase Control Data Demonstrates Benefit of Challenge Study Approach
PHASE 1 CONTROL DATA DEMONSTRATES BENEFIT OF CHALLENGE STUDY APPROACH For personal use only Endy et al, J Inf Dis 2021 Exemplary data from untreated subjects in a Phase 1 challenge trial. ISLAND PHARMACEUTICALS 9 November 2024
Slide 10: Safety Review Committee Recommendation
SAFETY REVIEW COMMITTEE RECOMMENDATION For personal use only • Safety Review Committee (SRC) has reviewed data from Phase 2a cohort • Primary endpoint of Phase 2a cohort was reduction in viremia (virus level in blood) • SRC conclusions: Administering ISLA-101 was safe Study achieved appropriate
Slide 11: H1 Milestone Achievements, H2 Target Milestones
H1 MILESTONE ACHIEVEMENTS, H2 TARGET MILESTONES** For personal use only H1 FY 2025 H2 FY 2025 (Jan – Jun 2025) (Jul – Dec 2024) • Obtain ethics approval for Phase 2 trial • Subjects dosed in Phase 2b trial arm • Screening subjects in Phase 2a/b trial • Data readout from Phase 2b study • Subjects dos
Slide 12: Island Pharmaceuticals
For personal use only Island Pharmaceuticals (ASX: ILA) islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ISLAND PHARMACEUTICALS 12 November 2024
Island Pharmaceuticals — Investor Presentation (November 2024) on 6ix